Literature DB >> 30801662

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.

L Prussick1, B Rothstein1, D Joshipura1, A Saraiya2, Y Turkowski3, R Abdat1, A Alomran1, P Zancanaro1, C Kachuk1, N Dumont1, A B Gottlieb4, D Rosmarin1.   

Abstract

Entities:  

Year:  2019        PMID： 30801662     DOI： 10.1111/bjd.17822

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  17 in total

1.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

2.  Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa.

Authors:  Kevin T Savage; Elena Gonzalez Brant; Monica Rosales Santillan; Peyton C Morss; Prerna Salian; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Int J Womens Dermatol       Date:  2020-02-25

Review 3.  Learning From Success and Failure: Biologics for Non-approved Skin Diseases.

Authors:  Reinhart Speeckaert; Jo Lambert; Nanja van Geel
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

Review 4.  Hidradenitis Suppurativa as a Potential Subtype of Autoinflammatory Keratinization Disease.

Authors:  Toshifumi Nomura
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

5.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

6.  Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report.

Authors:  Pelin Esme; Gulsen Akoglu; Ercan Caliskan
Journal:  Skin Appendage Disord       Date:  2020-12-09

Review 7.  Quality of Life in Hidradenitis Suppurativa: An Update.

Authors:  Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

Review 8.  Hidradenitis suppurativa: infection, autoimmunity, or both?

Authors:  Costas A Constantinou; George E Fragoulis; Elena Nikiphorou
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-30       Impact factor: 5.346

Review 9.  [Hidradenitis suppurativa /acne inversa-surgical options, reconstruction and combinations with drug therapies-an update].

Authors:  P Cramer; S Schneider-Burrus; M Kovács; L Scholl; M Podda; F G Bechara
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

10.  COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.

Authors:  Andrea Chiricozzi; Simone Garcovich; Dalma Malvaso; Giulia Giovanardi; Ketty Peris
Journal:  Int J Dermatol       Date:  2020-09-23       Impact factor: 3.204
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.